Discovering biased GPCR ligands that unlock new biology and avoid side effects as medicines for cardiovascular diseases, pain and inflammation
- Year invested 2008
- Investment Stage Early
- Sectors
- Investment Status Historic
- Website trevenainc.com
- Company Status IPO/Public (NASDAQ: TRVN)